Yue Wei, Ming Qian-Liang, Lin Bing, Rahman Khalid, Zheng Cheng-Jian, Han Ting, Qin Lu-Ping
a Department of Pharmacognosy, School of Pharmacy , Second Military Medical University , Shanghai , China .
b School of Life Science , East China Normal University , Shanghai , China .
Crit Rev Biotechnol. 2016;36(2):215-32. doi: 10.3109/07388551.2014.923986. Epub 2014 Jun 25.
The development of plant tissue (including organ and cell) cultures for the production of secondary metabolites has been underway for more than three decades. Plant cell cultures with the production of high-value secondary metabolites are promising potential alternative sources for the production of pharmaceutical agents of industrial importance. Medicinal plant cell suspension cultures (MPCSC), which are characterized with the feature of fermentation with plant cell totipotency, could be a promising alternative "chemical factory". However, low productivity becomes an inevitable obstacle limiting further commercialization of MPCSC and the application to large-scale production is still limited to a few processes. This review generalizes and analyzes the recent progress of this bioproduction platform for the provision of medicinal chemicals and outlines a range of trials taken or underway to increase product yields from MPCSC. The scale-up of MPCSC, which could lead to an unlimited supply of pharmaceuticals, including strategies to overcome and solution of the associated challenges, is discussed.
利用植物组织(包括器官和细胞)培养生产次生代谢产物的研究已经开展了三十多年。能够产生高价值次生代谢产物的植物细胞培养物有望成为生产具有工业重要性的药物制剂的潜在替代来源。药用植物细胞悬浮培养物(MPCSC)具有植物细胞全能性发酵的特点,可能是一个有前景的替代“化学工厂”。然而,低生产率成为限制MPCSC进一步商业化的一个不可避免的障碍,其在大规模生产中的应用仍然仅限于少数工艺。本综述总结并分析了这个用于生产药用化学品的生物生产平台的最新进展,并概述了为提高MPCSC产品产量而采取或正在进行的一系列试验。还讨论了MPCSC的扩大规模,这可能带来药品的无限供应,包括克服相关挑战的策略和解决方案。